{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:03:07Z","timestamp":1780470187613,"version":"3.54.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD), a major microvascular complication of diabetes, represents the leading cause of end-stage renal disease globally. Jinlida Granule (JLD), a multi-botanical Traditional Chinese Medicine preparation, has shown potential in type 2 diabetes management; however, a comprehensive systematic evaluation of its efficacy and safety specifically for DKD is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the efficacy and safety of JLD for DKD through a meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic search of Chinese and English databases and clinical trial registries for randomized controlled trials (RCTs) on JLD for DKD from inception to 9 October 2025. Two researchers independently performed literature screening, data extraction, and quality assessment using the Cochrane Risk of Bias (RoB) 2 tool. Meta-analysis was conducted with a random-effects model using STATA 15.0 and Review Manager 5.4. Subgroup and sensitivity analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twelve RCTs involving 1,341 patients were included. JLD was associated with significant reductions in serum creatinine (MD \u221230.54\u00a0\u03bcmol\/L, 95% CI \u221237.61 to \u221223.47; I\n                      <jats:sup>2<\/jats:sup>\n                      = 94%), blood urea nitrogen (MD \u22120.95\u00a0mmol\/L, 95% CI \u22121.29 to \u22120.60; I\n                      <jats:sup>2<\/jats:sup>\n                      = 79%), urinary albumin excretion rate (MD \u221227.09\u00a0mg\/24\u00a0h, 95% CI \u221229.16 to \u221225.02; I\n                      <jats:sup>2<\/jats:sup>\n                      = 94%), and HbA1c (MD \u22120.86%, 95% CI \u22121.23% to \u22120.49%; I\n                      <jats:sup>2<\/jats:sup>\n                      = 83%). Improvements were also observed in lipid profiles and inflammatory markers. Subgroup analyses suggested greater benefit in early-stage DKD and with specific combination regimens. Adverse events did not differ significantly between groups (RR 0.86, 95% CI 0.50\u20131.48). Substantial heterogeneity was noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence suggests that adjunctive JLD may provide multifaceted clinical benefits for DKD patients, with a comparable safety profile. However, these findings should be interpreted cautiously given the moderate to high risk of bias and considerable heterogeneity. Well-designed, large-scale RCTs are required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251178318<\/jats:ext-link>\n                      , identifier [CRD420251178318].\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1761454","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:07:51Z","timestamp":1780466871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of jinlida granule in the treatment of diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Qi","family":"Yong","sequence":"first","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxi","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bai","sequence":"additional","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejiang","family":"Ye","sequence":"additional","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]},{"name":"Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cytogfr.2025.05.007","article-title":"Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression","volume":"84","author":"Ansari","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/ajhp\/zxaf044","article-title":"KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: a primer on what pharmacists need to know","volume":"82","author":"Awdishu","year":"2025","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B5","first-page":"2670","article-title":"Observation on efficacy of tongxinluo capsules combined with jinlida granules in improving urine protein and renal function of patients with stage IV diabetic nephropathy","volume":"14","author":"Chen","year":"2019","journal-title":"World Chin. Med."},{"key":"B6","first-page":"3186","article-title":"Effect of tongxinluo capsule combined with jinlida granule on TGF-\u03b21\/Smad signaling pathway in diabetic kidney disease rats","volume":"34","author":"Chen","year":"2019","journal-title":"Chin. J. Tradit. Chin. Med. Pharm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"6651075","DOI":"10.1155\/2021\/6651075","article-title":"The role of cell division autoantigen 1 (CDA1) in renal fibrosis of diabetic nephropathy","volume":"2021","author":"Chen","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"115088","DOI":"10.1016\/j.biopha.2023.115088","article-title":"Advances in the pharmacological study of Chinese herbal medicine to alleviate diabetic nephropathy by improving mitochondrial oxidative stress","volume":"165","author":"Chen","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B9","volume-title":"Pharmacopoeia of the People\u2019s Republic of China","author":"Commission","year":"2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"F135","DOI":"10.1152\/ajprenal.00047.2023","article-title":"Redox regulation in diabetic kidney disease","volume":"325","author":"Daehn","year":"2023","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B12","first-page":"439","article-title":"Clinical efficacy analysis of jinlida granule combined with liraglutide in patients with early diabetic kidney disease","volume":"18","author":"Deng","year":"2020","journal-title":"J. Bethune Mil. Med. Coll."},{"key":"B13","doi-asserted-by":"publisher","first-page":"118424","DOI":"10.1016\/j.jep.2024.118424","article-title":"The mechanisms underlying Chinese medicines to treat inflammation in diabetic kidney disease","volume":"333","author":"Deng","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"key":"B15","first-page":"425","article-title":"Efficacy observation of jinlida granule combined with tongxinluo capsule in treating diabetic kidney disease","volume":"11","author":"Du","year":"2012","journal-title":"Chin. J. Difficult Complic. Cases"},{"key":"B16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B17","doi-asserted-by":"publisher","first-page":"102426","DOI":"10.1016\/j.eclinm.2024.102426","article-title":"Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study","volume":"68","author":"Forbes","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"key":"B19","article-title":"Meta-regression","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12967-025-06307-7","article-title":"Important regulatory role of mitophagy in diabetic microvascular complications","volume":"23","author":"Hu","year":"2025","journal-title":"J. Transl. Med."},{"key":"B21","volume-title":"Classics, T. (-200) Yellow Emperor\u2019s Inner Canon. TCM Classics","author":"Jing","year":"2011"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1177\/08971900241262381","article-title":"Updates in chronic kidney disease","volume":"37","author":"Johnson","year":"2024","journal-title":"J. Pharm. Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1142\/S0192415X25500260","article-title":"Traditional Chinese medicine formulae and Chinese patent medicines for the treatment of diabetic kidney disease: efficacies and mechanisms","volume":"53","author":"Li","year":"2025","journal-title":"Am. J. Chin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3969\/j.issn.2096-3327.2024.02.015","article-title":"Clinical efficacy of jinlida granule combined with Tripterygium wilfordii polyglycoside tablets in treating diabetic kidney disease and its effect on immune function","volume":"21","author":"Liu","year":"2024","journal-title":"Chin. J. Ration. Drug Use"},{"key":"B25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3969\/j.issn.2096-3327.2024.02.015","article-title":"Clinical observation of jinlida combined with tongxinluo in treatment of type 2 diabetic kidney disease under the guidance of collateral vessel theory","volume":"25","author":"Liu","year":"2019","journal-title":"Chin. J. Exp. Tradit. Med. Form."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1142805","DOI":"10.3389\/fendo.2023.1142805","article-title":"Chinese herbal medicine and its active compounds in attenuating renal injury via regulating autophagy in diabetic kidney disease","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s10020-024-01020-5","article-title":"Targeting programmed cell death in diabetic kidney disease: from molecular mechanisms to pharmacotherapy","volume":"30","author":"Liu","year":"2024","journal-title":"Mol. Med."},{"key":"B28","first-page":"881","article-title":"Efficacy observation of jinshuibao tablets combined with jinlida granule in treating diabetic kidney disease","volume":"29","author":"Lou","year":"2018","journal-title":"J. Aerosp. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.16781\/j.0258-879x.2016.08.1028","article-title":"Protective effect of jinlida granules on kidney in type 1 diabetic rats","volume":"37","author":"Lu","year":"2016","journal-title":"Acad. J. Second Mil. Med. Univ."},{"key":"B30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/ANNALS-24-01926","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2024 clinical practice guideline","volume":"178","author":"Madero","year":"2025","journal-title":"Ann. Intern Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.3390\/cells11223635","article-title":"Mitochondrial contribution to inflammation in diabetic kidney disease","volume":"11","author":"Mitrofanova","year":"2022","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","first-page":"Cd015907","DOI":"10.1002\/14651858.cd015907.pub2","article-title":"Thiazolidinediones for people with chronic kidney disease and diabetes","volume":"11","author":"Natale","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.4093\/dmj.2024.0535","article-title":"Inflammatory milieu by crosstalk between glomerulus and proximal tubular cells in type 2 diabetes mellitus kidney disease","volume":"49","author":"Park","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"B34","first-page":"105","article-title":"Clinical effect of jinlida granule in patients with diabetic kidney disease","volume":"23","author":"Ren","year":"2019","journal-title":"J. Clin. Med. Pract."},{"key":"B35","volume-title":"Jinlida Granules (Jin Li Da Ke Li)","year":"2025"},{"key":"B36","first-page":"69","article-title":"Efficacy observation of jinlida granule combined with benazepril in elderly patients with type 2 diabetic kidney disease","volume":"12","author":"Su","year":"2020","journal-title":"Clin. J. Chin. Med."},{"key":"B37","first-page":"377","article-title":"Effect of jinlida granule on serum vascular endothelial growth factor and insulin-like growth factor-1 in patients with diabetic kidney disease","volume":"20","author":"Su","year":"2017","journal-title":"Chin. Gen. Pract."},{"key":"B38","first-page":"561","article-title":"Pathological mechanism of diabetic kidney disease and the therapeutic potential of jinlida granules by RNA sequencing integrated with network pharmacology","volume":"45","author":"Su","year":"2025","journal-title":"Chin. J. Hosp. Pharm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3892\/ijmm.2024.5467","article-title":"Jinlida granules alleviate podocyte apoptosis and mitochondrial dysfunction via the AMPK\/PGC-1\u03b1 pathway in diabetic nephropathy","volume":"55","author":"Sun","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/biom12091227","article-title":"Oxidative stress and NRF2\/KEAP1\/ARE pathway in diabetic kidney disease (DKD): new perspectives","volume":"12","author":"Tanase","year":"2022","journal-title":"Biomolecules"},{"key":"B42","first-page":"1290","article-title":"Effect of jinlida granule combined with benazepril on blood glucose, renal function and serum vascular endothelial growth factor in patients with diabetic kidney disease","volume":"34","author":"Wang","year":"2023","journal-title":"Mod. Diagn. Treat."},{"key":"B43","doi-asserted-by":"publisher","first-page":"932649","DOI":"10.3389\/fendo.2023.932649","article-title":"Promising therapeutic mechanism for Chinese herbal medicine in ameliorating renal fibrosis in diabetic nephropathy","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e106220","DOI":"10.1136\/bmjopen-2025-106220","article-title":"Efficacy and safety of finerenone combined with sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease: protocol for a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2025","journal-title":"BMJ Open"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s12325-025-03228-1","article-title":"Guideline-recommended disease-modifying therapies for patients with cardiorenal disease: a call-to-action narrative review","volume":"42","author":"Wanner","year":"2025","journal-title":"Adv. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"10822","DOI":"10.3390\/ijms221910822","article-title":"Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists","volume":"22","author":"Winiarska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.16781\/j.0258-879x.2016.08.1028","article-title":"Clinical efficacy analysis of jinlida granule combined with dapagliflozin in patients with early diabetic kidney disease","volume":"38","author":"Xia","year":"2025","journal-title":"Huaxia Med."},{"key":"B48","first-page":"936","article-title":"Effect of jinlida granule combined with tongxinluo capsule on micro-inflammatory state and renal function protection in patients with early diabetic kidney disease","volume":"17","author":"Xu","year":"2018","journal-title":"Chin. J. Difficult Complic. Cases"},{"key":"B49","article-title":"Effect of jinlida granule on TGF-\u03b21-P38MAPK-FN pathway in rats with diabetic kidney disease","volume-title":"Proceedings of the 12th National Congress of Endocrinology, Chinese Medical Association","author":"Xue","year":"2013"},{"key":"B50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.apsb.2015.07.009","article-title":"5'-Monophosphate-activated protein kinase (AMPK) improves autophagic activity in diabetes and diabetic complications","volume":"6","author":"Yao","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"B51","first-page":"215","volume-title":"J. Difficult Complicated Cases","author":"Yiling","year":"2004"},{"key":"B52","volume-title":"Renal Protective Effect of Tongxinluo Ultramicro Powder Combined with Jinlida Granule on Diabetic Rats and its Influence on TGF-\u03b21\/Smad Signaling Pathway. Master\u2019s thesis","author":"Zhang","year":"2014"},{"key":"B53","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1111\/dom.70118","article-title":"An SGLT2 inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats","volume":"27","author":"Zhang","year":"2025","journal-title":"Diabetes Obes. Metab."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1761454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:07:59Z","timestamp":1780466879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1761454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":53,"alternative-id":["10.3389\/fphar.2026.1761454"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1761454","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1761454"}}